<SEC-DOCUMENT>0001213900-21-038381.txt : 20210723
<SEC-HEADER>0001213900-21-038381.hdr.sgml : 20210723
<ACCEPTANCE-DATETIME>20210723163045
ACCESSION NUMBER:		0001213900-21-038381
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210723
DATE AS OF CHANGE:		20210723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-217956
		FILM NUMBER:		211111235

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>ea144449-424b4_citius.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed pursuant to Rule
424(b)(4)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-217956</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,622,989
Shares of Common Stock Issuable upon Exercise of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>65,940
Shares of Common Stock Issuable upon Exercise of Underwriter Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the issuance of up to 1,622,989 shares of our common stock, $0.001 par value per share, issuable upon the exercise
of outstanding warrants, at an exercise price of $4.125 per share, that were issued by us to investors on August 8, 2017 (referred to
as the Warrants), pursuant to a master warrant agent agreement, dated as of August 3, 2017, or the Warrant Agreement, between us and
VStock Transfer, LLC. The Warrants expire on August 2, 2022. This prospectus also relates to the issuance of&nbsp;65,940 shares of common
stock&nbsp;underlying the underwriter warrants issued by us on August 8, 2017 (referred to as the Underwriter Warrants), at an exercise
price of $4.5375 per share, all of which expire on August 2, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; on page 8 of this prospectus to read about factors
you should consider before investing in our securities. <FONT STYLE="background-color: white">See &ldquo;Where You Can Find More
Information&rdquo; and &ldquo;Incorporation of Documents by Reference&rdquo; for more information.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the Nasdaq Capital Market under the symbol
&ldquo;CTXR&rdquo;. The last reported sale price of our common stock on July 8, 2021 was $2.16 per share. We recommend that you obtain
current market quotations for our common stock prior to making an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is&nbsp;July 8, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 90%; text-indent: 0"><A HREF="#G_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Note Regarding Forward-Looking Statements and Industry Data</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Our Capital Stock</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional Information</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="#G_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Documents by Reference</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="G_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a post-effective amendment to a registration statement, originally on Form S-1 and now on Form S-3, that we filed
with the Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration or continuous offering process.&nbsp;&nbsp;This
prospectus relates to the offer and sale of up to 1,622,989 shares of our common stock to be offered from time to time upon exercise
of the Warrants and up to 65,940 shares of our common stock to be offered from time to time upon exercise of the Underwriter Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information that we have provided or incorporated by reference in this prospectus. We have not authorized anyone
to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent
anything not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on
it. You should assume that the information in this prospectus or incorporated herein is accurate only as of the date on the cover of
the document and that any information included in this prospectus or that we have incorporated by reference herein is accurate only as
of the date of the such document, regardless of the time of delivery of this prospectus or any sale of a security. Our business, financial
condition, results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
urge you to carefully read this prospectus, together with the information incorporated herein by reference as described under the heading
&ldquo;Where You Can Find Additional Information&rdquo; and &ldquo;Incorporation of Documents by Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, we use the terms &ldquo;Citius&rdquo;, &ldquo;the Company&rdquo;, &ldquo;our company&rdquo;, &ldquo;we&rdquo;,
&ldquo;us&rdquo;, and &ldquo;our&rdquo; in this prospectus to refer to the consolidated operations of Citius Pharmaceuticals, Inc. and
its consolidated subsidiaries as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including
Mino-Lok&reg;. All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective
owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned
in this prospectus, appear with the trade name, trademark or service mark notice and then throughout the remainder of this prospectus
without trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive
or generic sense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="G_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the documents incorporated by reference into this prospectus, contain forward-looking statements that are based on our
management&rsquo;s belief and assumptions and on information currently available to our management. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance,
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. The statements contained in this prospectus and the documents incorporated by reference into this
prospectus that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements in this prospectus include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number, designs, timing, costs and results of our pre-clinical and clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            regulatory review process and any regulatory approvals that may be issued or denied by the
                                            U.S. Food and Drug Administration or other regulatory agencies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            need for, and ability to raise, additional capital;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commercial success and market acceptance of any of our product candidates that are approved
                                            for marketing in the United States or other countries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            accuracy of our estimates and of third-party estimates of the size and characteristics of
                                            the markets that may be addressed by our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manufacture sufficient amounts of our product candidates for clinical trials and,
                                            if approved, our products for commercialization activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            need to secure collaborators to license, manufacture, market and sell any products for which
                                            we receive regulatory approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to protect our intellectual property and operate our business without infringing
                                            upon the intellectual property rights of others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            medical benefits, effectiveness and safety of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            safety and efficacy of medicines or treatments introduced by competitors that are targeted
                                            to indications for which our product candidates are being developed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            current or prospective collaborators&rsquo; compliance or non-compliance with their obligations
                                            under our agreements with them;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of the COVID-19 pandemic on our clinical trials, business and operations; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            factors discussed elsewhere in this prospectus or incorporated by reference herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terminology such as &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;should&rdquo;,
&ldquo;expects&rdquo;, &ldquo;intends&rdquo;, &ldquo;plans&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;, &ldquo;estimates&rdquo;,
&ldquo;predicts&rdquo;, &ldquo;potential&rdquo;, &ldquo;continue&rdquo; or the negative of these terms or other comparable terminology.
These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus or incorporated by reference herein. Actual events or results may vary significantly
from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
You should read this prospectus and the documents that we incorporate by reference in this prospectus and have filed with the SEC as
exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future
results may be materially different from any future results expressed or implied by these forward-looking statements. The forward-looking
statements in this prospectus or incorporated herein by reference represent our views as of the date of this prospectus or the document
incorporated by reference herein. We anticipate that subsequent events and developments will cause our views to change. However, while
we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except
to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views
as of any date subsequent to the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, the documents incorporated by reference into this prospectus and the documents that we have filed as exhibits to the registration
statement, of which this prospectus is a part, includes statistical and other industry and market data that we obtained from industry
publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and
studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee
the accuracy or completeness of such information. We believe that the data obtained from these industry publications and third-party
research, surveys and studies are reliable. We are ultimately responsible for all disclosure included in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus, as supplemented and amended. We have not authorized anyone to provide
you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information
in this prospectus may only be accurate on the date of this prospectus.</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="G_003"></A>THE
COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Citius
Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a specialty pharmaceutical company dedicated to the development and
commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products
and mesenchymal stem cell therapy. Our goal generally is to achieve leading market positions by providing therapeutic products that address
unmet medical needs yet have a lower development risk than usually is associated with new chemical entities. New formulations of previously
approved drugs with substantial existing safety and efficacy data are a core focus. We seek to reduce development and clinical risks
associated with drug development, yet still focus on innovative applications. Our strategy centers on products that have intellectual
property and regulatory exclusivity protection, while providing competitive advantages over other existing therapeutic approaches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mino-Lok</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mino-Lok
is a patented solution containing minocycline, disodium ethylenediaminetetraacetic acid (edetate), and ethyl alcohol, all of which act
synergistically to treat and salvage infected central venous catheters (&ldquo;CVCs&rdquo;) in patients with catheter related bloodstream
infections (&ldquo;CRBSIs&rdquo;). Mino-Lok breaks down biofilm barriers formed by bacterial colonies, eradicates the bacteria, and provides
anti-clotting properties to maintain patency in CVCs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
administration of Mino-Lok consists of filling the lumen of the catheter with 0.8 ml to 2.0 ml of Mino-Lok solution. The catheter is
then &ldquo;locked&rdquo;, meaning that the solution remains in the catheter without flowing into the vein. The lock is maintained for
a dwell-time of two hours while the catheter is not in use. If the catheter has multiple lumens, all lumens may be locked with the Mino-Lok
solution either simultaneously or sequentially. If patients are receiving continuous infusion therapy, the catheters alternate between
being locked with the Mino-Lok solution and delivering therapy. The Mino-Lok therapy is two hours per day for at least five days, usually
with two additional locks in the subsequent two weeks. After locking the catheter for two hours, the Mino-Lok solution is aspirated,
and the catheter is flushed with normal saline. At that time, either the infusion will be continued, or will be locked with the standard-of-care
lock solution until further use of the catheter is required. In a clinical study conducted by MD Anderson Cancer Center (&ldquo;MDACC&rdquo;),
there were no serum levels of either minocycline or edetate detected in the sera of several patients who underwent daily catheter lock
solution with minocycline and edetate (&ldquo;M-EDTA&rdquo;) at the concentration level proposed in the Mino-Lok treatment. Thus, it
has been demonstrated that the amount of either minocycline or edetate that leaks into the serum is very low or none at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phase
2b Results</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
April 2013 to July 2014, 30 patients with CVC-related bloodstream infection were enrolled at MDACC in a prospective Phase 2b study. Patients
received Mino-Lok therapy for two hours once daily for a minimum of five days within the first week, followed by two additional locks
within the next two weeks. Patients were followed for one month post-lock therapy. Demographic information, clinical characteristics,
laboratory data, therapy, as well as adverse events and outcome were collected for each patient. Median age at diagnosis was 56 years
(range: 21-73 years). In all patients, prior to the use of lock therapy, systemic treatment with a culture-directed, first-line intravenous
antibiotic was started. Microbiological eradication was achieved at the end of therapy in all cases. None of the patients experienced
any serious adverse event related to the lock therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
active arm, which is the Mino-Lok treated group of patients, was then compared to 60 patients in a matched cohort that experienced removal
and replacement of their CVCs within the same contemporaneous timeframe. The patients were matched for cancer type, infecting organism,
and level of neutropenia. All patients were cancer patients and treated at MDACC. The efficacy of Mino-Lok therapy was 100% in salvaging
CVCs, demonstrating equal effectiveness to removing the infected CVC and replacing it with a new catheter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main purpose of the study was to show that Mino-Lok therapy was at least as effective as the removal and replacement of CVCs when CRBSIs
are present, and that the safety was better, that is, the complications of removing an infected catheter and replacing with a new one
could be avoided. In addition to having a 100% efficacy rate with all CVCs being salvaged, Mino-Lok therapy had no significant adverse
events (&ldquo;SAEs&rdquo;), compared to an 18% SAE rate in the matched cohort where patients had the infected CVCs removed and replaced
with a fresh catheter. There were no overall complication rates in the Mino-Lok arm group compared to 11 patients with events (18)% in
the control group. These events included bacterial relapse (5)% at four weeks post-intervention, and a number of complications associated
with mechanical manipulation in the removal or replacement procedure for the catheter (10)% or development of deep-seated infections
such as septic thrombophlebitis and osteomyelitis (8)%. As footnoted, six patients had more than one complication in the control arm
group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mino-Lok Arm</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Control Arm</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Parameter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">N</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(%)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">N</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(%)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-weight: bold">Patients</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">30</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(100</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)%</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">60</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(100</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cancer type</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>- Hematologic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">- Solid tumor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">ICU Admission</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">4</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(13</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">4</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(7</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Mech. Ventilator</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(10</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">0</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(0</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Bacteremia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>- Gram+</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57</TD><TD STYLE="text-align: left">)*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>- Gram-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Neutropenia (&lt;500)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">19</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(63</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">36</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(60</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Microbiologic Eradication</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">30</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(100</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">60</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(100</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>- Relapse</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Complications</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">0</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(0</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(13</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SAEs related to R&amp;R</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">0</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(0</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(10</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Overall Complication Rate</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">0</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(0</TD><TD STYLE="font-weight: bold; text-align: left">)%</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">11</TD><TD STYLE="font-weight: bold; text-align: left">**</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(18</TD><TD STYLE="font-weight: bold; text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 polymicrobial patient
    had a Gram+ and a Gram- organism cultured</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 patients had &gt; 1 complication</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Source:
Dr. Issam Raad, Antimicrobial Agents and Chemotherapy, June 2016, Vol. 60 No. 6, Page 3429</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phase
3 Trial</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016, the Company initiated site recruitment for Phase 3 clinical trials. From initiation through the first quarter of 2017,
the Company received input from several sites related to the control arm as being less than standard-of-care for some of the respective
institutions. The Company worked closely with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) with respect to the design of
the Phase 3 trial and received feedback on August 17, 2017. The FDA stated that they recognized that there is an unmet medical need in
salvaging infected catheters and agreed that an open label, superiority design would address the Company&rsquo;s concerns and would be
acceptable to meet the requirements of a new drug application. The Company amended the Phase 3 study design to remove the saline and
heparin placebo control arm and to use an active control arm that conforms with today&rsquo;s current standard-of-care. Patient enrollment
commenced in February 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Mino-Lok Phase 3 trial was originally planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There
will be interim analyses at both the 50% and 75% points of the trial as measured by the number of patients treated. As of March 31, 2021,
there are 25 active sites currently enrolling patients including such academic centers as MDACC, Henry Ford Health Center, Georgetown
University Medical Center, and others. There is one additional medical center in startup mode. There are no other remaining sites in
feasibility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, the Company announced that the FDA agreed to a new primary efficacy endpoint of &ldquo;time to catheter failure&rdquo;
in comparing Mino-Lok to the antibiotic lock control arm. This change in the trial design reduced the required patient sample size of
the trial from 700 subjects to approximately 144 available subjects to achieve the pre-specified 92 catheter failure events needed to
conclude the trial. Additionally, the Company submitted a response to the FDA that it will implement this change in the primary endpoint
and expected it to result in less than 150 subjects needed in its Phase 3 trial. The new primary endpoints require that the time to catheter
failure be at least 38 days for Mino-Lok versus 21 days for the standard of care antibiotic locks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the FDA agreed that the patient sample size of approximately 144 patients was acceptable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, the Company announced that the Phase 3 trial had reached the 40% completion triggering an interim futility analysis by
the data monitoring committee (the &ldquo;DMC&rdquo;). The DMC is an independent panel of experts that review progress regarding the
safety and efficacy of drugs in clinical trials, and to determine if the trial may be futile in achieving its endpoints or if the trial
should be modified in any way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the DMC convened and recommended that the trial continue with no changes because the analysis showed a positive outcome,
as it met the prespecified interim futility analysis criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, we announced that we are providing free access to Mino-Lok for healthcare providers under an Expanded Access protocol to ease
the burden associated with the COVID-19 pandemic. Through the Expanded Access protocol, an infected central venous catheter can now be
treated with Mino-Lok, potentially avoiding the need for the removal and replacement procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, we announced that we had received positive feedback from the FDA on our proposed catheter compatibility studies for Mino-Lok.
The studies, if and when successfully completed, should allow Mino-Lok to be labeled for use with all commercially available CVCs and
peripherally inserted central catheters (PICCs) on the U.S. market. It is further assumed that these studies will meet European and world
standards. The ability to be labeled without restrictions with respect to catheter type would allow Mino-Lok unrestricted access to the
full U.S. and world markets for an effective antibiotic lock therapy for central line associated blood stream infections (&ldquo;CLABSIs&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, we announced that another DMC meeting was held to review the data being generated and analyzed in the Mino-Lok Phase
3 trial based on progress to date, and to make recommendations to us as to any action that may be necessary regarding the study.
After reviewing these data, the DMC members stated that they did not find any safety signals; and they also recommended continuing
the trial without any modifications. The DMC further conducted an&nbsp;<I>ad hoc</I>&nbsp;meeting and agreed with the Company that a
75% interim analysis be conducted as planned in which superior efficacy is evaluated. Due to the COVID-19 pandemic, the interim
analysis will be performed at the 65% threshold. To counter the impact of COVID-19, we have aggressively pursued outreach programs
with webinars and other remote communications, and were able to add randomized patients bringing us closer to the number of events
for the &ldquo;superiority&rdquo; analysis. We scheduled a meeting with the DMC for late June 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
July 1, 2021, we announced that the DMC recommended proceeding with the trial as planned. The DMC did not identify any safety
concerns and also recommended no modifications to the protocol-defined sample size or power to achieve the primary endpoint. We
expect to file a New Drug Application, or NDA, in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, the Company announced that the three registration batches for all components of Mino Lok were manufactured and that clinical
sites were resupplied with registration product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company announced that the three components of Mino-Lok, minocycline, disodium edetate (&ldquo;EDTA&rdquo;), and ethanol,
were superior to EDTA and ethanol in their ability to eradicate resistant staphylococcal biofilms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fast
Track Designation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, the Company received official notice from the FDA that the investigational program for Mino-Lok was granted &ldquo;Fast
Track&rdquo; status. Fast Track is a designation that expedites FDA review to facilitate development of drugs which treat a serious or
life-threatening condition and fill an unmet medical need. A drug that receives Fast Track designation is eligible for the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More frequent meetings with the FDA to discuss the
    drug&rsquo;s development plan and ensure collection of appropriate data needed to support drug approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More frequent written correspondence from the FDA about
    the design of the clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority review to shorten the FDA review process for
    a new drug from ten months to six months; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rolling review, which means Citius can submit completed
    sections of its NDA for review by the FDA, rather than waiting until every section of the application is completed before the entire
    application can be reviewed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mino-Lok
International Study</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, data from an international study on Mino-Lok was presented at the Infectious Disease Conference (&ldquo;ID Week&rdquo;)
in San Diego, California. The 44-patient study was conducted in Brazil, Lebanon, and Japan and showed Mino-Lok therapy was an effective
intervention to salvage long-term, infected CVCs in CRBSIs in patients who had cancer with limited vascular access. This study showed
95% effectiveness for Mino-Lok therapy in achieving microbiological eradication of the CVCs as compared to 83% for the control. The single
failure in the Mino-Lok arm was due to a patient with&nbsp;<I>Burkholderia cepacia</I>&nbsp;that was resistant to all antibiotics tested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stability
Patent Application for Mino-Lok</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) issued U.S. Patent No. 10,086,114, entitled &ldquo;Antimicrobial
Solutions with Enhanced Stability.&rdquo; This invention overcomes limitations in mixing antimicrobial solutions in which components
have precipitated because of physical and/or chemical factors, thus limiting the stability of the post-mix solutions. The scientists
and technologists at MDACC have been able to improve the stability of the post-mixed solutions through adjustments of the post-mixed
pH of the solution. This may allow for longer storage time of the ready-to-use solution. Citius holds the exclusive worldwide license
which provides access to this patented technology for development and commercialization of Mino-Lok.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2019, the European Patent Office (&ldquo;EPO&rdquo;) granted European Patent No. 3370794, entitled &ldquo;Antimicrobial Solutions
with Enhanced Stability.&rdquo; The grant of this European patent strengthens the intellectual property protection for Mino-Lok through
November of 2036. This invention overcomes limitations in mixing antimicrobial solutions, in which components have precipitated because
of physical and/or chemical factors, thus limiting the stability of the post-mix solutions. The scientists and technologists at MDACC
have been able to improve the stability of the post-mixed solutions through adjustments of the post-mixed pH of the solution. This may
allow for longer storage time of the ready-to-use solution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mino-Wrap</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 2, 2019, we entered into a patent and technology license agreement with the Board of Regents of the University of Texas System
on behalf of MDACC, whereby we in-licensed exclusive worldwide rights to the patented technology for any and all uses relating to breast
implants, specifically the Mino-Wrap technology. This includes rights to U.S. Patent No. 9,849,217, which was issued on December 16,
2017. We intend to develop Mino-Wrap as a liquefying, gel-based wrap containing minocycline and rifampin for the reduction of infections
associated with breast implants following breast reconstructive surgeries. We are required to use commercially reasonable efforts to
commercialize Mino-Wrap under several regulatory scenarios and achieve milestones associated with these regulatory options leading to
an approval from the FDA. Mino-Wrap will require pre-clinical development prior to any regulatory pathway. In July 2019, we announced
that we intend to pursue the FDA&rsquo;s Investigational New Drug (&ldquo;IND&rdquo;) regulatory pathway for the development of Mino-Wrap.
On August 4, 2020, we announced that we had submitted a briefing package to the FDA for a pre-IND consultation on Mino-Wrap. In December
2020, we reported the FDA response to the briefing package and commented that the FDA was in general agreement with our planned pre-clinical
program and gave further guidance on our clinical plans. Following this guidance from the FDA, we are conducting <I>in vitro</I> experiments
and product characterization studies for Mino-Wrap. Animal studies are underway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Halo-Lido</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Halo-Lido
is a topical formulation of halobetasol propionate, a corticosteroid and lidocaine that is intended for the treatment of hemorrhoids.
To our knowledge, there are currently no FDA-approved prescription drug products for the treatment of hemorrhoids. Some physicians are
known to prescribe topical steroids for the treatment of hemorrhoids. In addition, there are various topical combination prescription
products containing halobetasol propionate along with lidocaine or pramoxine, each a topical anesthetic, that are prescribed by physicians
for the treatment of hemorrhoids. These products contain drugs that were in use prior to the start of the Drug Efficacy Study Implementation
(&ldquo;DESI&rdquo;) program and are commonly referred to as DESI drugs. However, none of these single-agent or combination prescription
products have been clinically evaluated for safety and efficacy and approved by the FDA for the treatment of hemorrhoids. Further, many
hemorrhoid patients use over the counter (&ldquo;OTC&rdquo;) products as their first line therapy. OTC products contain any one of several
active ingredients including glycerin, phenylephrine, pramoxine, white petrolatum, shark liver oil and/or witch hazel, for symptomatic
relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Development
of Hemorrhoids Drugs</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemorrhoids
are a common gastrointestinal disorder, characterized by anal itching, pain, swelling, tenderness, bleeding and difficulty defecating.
In the U.S., hemorrhoids affect nearly 5% of the population, with approximately 10 million persons annually admitting to having symptoms
of hemorrhoidal disease. Of these persons, approximately one third visit a physician for evaluation and treatment of their hemorrhoids.
The data also indicate that for both sexes a peak of prevalence occurs from age 45 to 65 years with a subsequent decrease after age 65
years. Caucasian populations are affected significantly more frequently than African Americans, and increased prevalence rates are associated
with higher socioeconomic status in men but not women. Development of hemorrhoids before age 20 is unusual. In addition, between 50%
and 90% of the general U.S., Canadian and European population will experience hemorrhoidal disease at least once in life. Although hemorrhoids
and other anorectal diseases are not life-threatening, individual patients can suffer from agonizing symptoms which can limit social
activities and have a negative impact on the quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemorrhoids
are defined as internal or external according to their position relative to the dentate line. Classification is important for selecting
the optimal treatment for an individual patient. Accordingly, physicians use the following grading system referred to as the Goligher&rsquo;s
classification of internal hemorrhoids:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 10%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grade I</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 90%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemorrhoids not prolapsed but bleeding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grade II</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hemorrhoids prolapse and reduce spontaneously with
    or without bleeding.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grade III</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prolapsed hemorrhoids that require reduction manually.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grade IV</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prolapsed and cannot be reduced including both internal
    and external hemorrhoids that are confluent from skin tag to inner anal canal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Development
Activities to Date</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fall of 2015, we completed dosing patients in a double-blind dose ranging placebo controlled Phase 2a study where six different formulations
containing hydrocortisone and lidocaine in various strengths were tested against the vehicle control. The objectives of this study were
to: (1) demonstrate the safety and efficacy of the formulations when applied twice daily for two weeks in subjects with Grade I or II
hemorrhoids, and (2) assess the potential contribution of lidocaine hydrochloride and hydrocortisone acetate, alone or in combination
for the treatment of symptoms of Goligher&rsquo;s Classification Grade I or II hemorrhoids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptom
improvement was observed based on a global score of disease severity (&ldquo;GSDS&rdquo;) and based on some of the individual signs and
symptoms of hemorrhoids, specifically itching and overall pain and discomfort. Within the first few days of treatment, the combination
products (containing both hydrocortisone and lidocaine) were directionally favorable versus the placebo and their respective individual
active treatment groups (e.g., hydrocortisone or lidocaine alone) in achieving &lsquo;almost symptom free&rsquo; or &lsquo;symptom free&rsquo;
status according to the GSDS scale. These differences suggest the possibility of a benefit for the combination product formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
results from adverse event reporting support the safety profile of all test articles evaluated in this study and demonstrate similar
safety profiles as compared to the vehicle. The safety findings were unremarkable. There was a low occurrence of adverse events and a
similar rate of treatment related adverse events across all treatment groups. The majority of adverse events were mild and only one was
severe. None of the adverse events were an SAE and the majority of adverse events were recovered/resolved at the end of the study. There
were only two subjects who were discontinued from the study due to adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the safety and dose-ranging information, information was obtained relating to the use of the GSDS as an assessment tool for
measuring the effectiveness of the test articles. Individual signs and symptoms were also assessed but can vary from patient to patient.
Therefore, the goal of the GSDS was to provide an assessment tool that could be used for all patients regardless of which signs and symptoms
they are experiencing. The GSDS proved to be a more effective tool for assessing the severity of the disease and the effectiveness of
the drug when compared to the assessment of the individual signs and symptoms. Citius believes that we can continue to develop this assessment
tool as well as other patient reported outcome endpoints for use in the next trials and in the pivotal trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Information
was also obtained about the formulation of the drug and the vehicle. As a result of this study, we believed that the performance of the
active arms of the study relative to the vehicle could be improved by re-formulating our topical preparation. Therefore, we initiated
work on vehicle formulation and evaluation of higher potency steroids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June and July 2016, we engaged the Dominion Group, a leading provider of healthcare and pharmaceutical marketing research services. The
primary market research was conducted to better understand the symptoms that are most bothersome to patients in order to develop meaningful
endpoints for the clinical trials. We also learned about the factors that drive patients to seek medical attention for hemorrhoids in
an effort to understand the disease&rsquo;s impact on quality of life. The results of this survey are able to help us develop patient
reported outcome evaluation tools. These tools can be used in clinical trials to evaluate the patients&rsquo; conditions and to assess
the performance of the test articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we announced that we had selected a higher potency corticosteroid in our steroid/anesthetic topical formulation program for
the treatment of hemorrhoids. The original topical preparation, which we referred to as Hydro-Lido or CITI-001, which was used in the
Phase 2a study, was a combination of hydrocortisone acetate and lidocaine hydrochloride. The new formulation, CITI-002, which we refer
to as Halo-Lido, combines lidocaine with the higher potency corticosteroid halobetasol propionate for symptomatic relief of the pain
and discomfort of hemorrhoids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
held a Type C meeting with the FDA in December 2017 to discuss the results of the Phase 2a study and to obtain the FDA&rsquo;s view on
development plans to support the potential formulation change for the planned Phase 2b study. We also requested the FDA&rsquo;s feedback
on our Phase 2b study design, including target patient population, inclusion/exclusion criteria, and efficacy endpoints. The pre-clinical
and clinical development programs for CITI-002 are planned to be similar to those conducted for the development of CITI-001 to support
the design for a planned Phase 3 clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA guided us to develop a novel patient-reported outcome, or PRO, instrument to assess clinical outcomes and efficacy of Halo-Lido.
The PRO is currently being reviewed by the FDA. Pending feedback from the FDA, we expect to file an Investigational New Drug application,
or IND, with the FDA and anticipate beginning a Phase 2b clinical study, both in the fourth quarter of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NoveCite</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In October 2020, we, through our subsidiary,
NoveCite, signed an exclusive agreement with Novellus Therapeutics Limited (&ldquo;Novellus&rdquo;), now a subsidiary of Brooklyn ImmunoTherapeutics,
Inc., to license iPSC-derived mesenchymal stem cells (iMSCs). Under this worldwide exclusive license, we will be focused on developing
cellular therapies. Specifically, we will seek to develop and commercialize the NoveCite mesenchymal stem cells (&ldquo;NC-<I>i</I>MSCs&rdquo;)
to treat acute respiratory conditions with a near term focus on ARDS associated with COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NC-<I>i</I>MSCs
are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human
donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges
(e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). NC-<I>i</I>MSCs overcome
these challenges because they:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are more potent and secrete exponentially higher levels
    of immunomodulatory proteins;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have practically unlimited supply for high doses and
    repeat doses;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are from a single donor and clonal so they are economically
    produced at scale with consistent quality and potency, as well as being footprint free (compared to viral reprogramming methods);
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have a significantly higher expansion capability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance
of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the
emergency authorization program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the Company announced interim data from a proof-of-concept large animal study of its NC-<I>i</I>MSC therapy for acute
inflammatory respiratory conditions including COVID-19 related ARDS. The available results of NC<I>-i</I>MSC therapy in the study show
improvement in critical parameters, such as improved oxygenation, less systemic shock, and reduced lung injury, compared to the control
group. The study was conducted in a widely accepted large animal model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to complete additional pre-clinical studies throughout 2021 and anticipates filing an IND by the end of the second quarter
of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
History and Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were founded as Citius Pharmaceuticals, LLC, a Massachusetts limited liability company, on January 23, 2007. On September 12, 2014, Citius
Pharmaceuticals, LLC entered into a Share Exchange and Reorganization Agreement, with Citius Pharmaceuticals, Inc. (formerly Trail One,
Inc.), a publicly traded company incorporated under the laws of the State of Nevada. Citius Pharmaceuticals, LLC became a wholly-owned
subsidiary of Citius. On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (&ldquo;LMB&rdquo;) as a wholly-owned subsidiary.
LMB was a pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infectives.
On September 11, 2020, we formed NoveCite, Inc. (&ldquo;NoveCite&rdquo;), a Delaware corporation, of which we own 75% of the issued and
outstanding capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016 and our telephone number is (908)
967-6677.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt"><B>Common stock offered by us</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Up to 1,622,989 shares of our common stock upon the exercise of Warrants and up to 65,940 shares of common stock upon the exercise of Underwriter Warrants. The Warrants have an exercise price of $4.125 per share and expire on August 2, 2022. The Underwriter Warrants have an exercise price of $4.5375 per share and expire on August 2, 2022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Common stock to be outstanding immediately after this offering</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">136,390,148&nbsp;shares, assuming the exercise in full of all Warrants and Underwriter Warrants for cash.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">We may receive up to a total of approximately $6,994,033 in gross proceeds if all of the Warrants
    and Underwriter Warrants are exercised for cash. We have not allocated any proceeds of such exercises to any particular purpose. See
    &ldquo;Use of Proceeds&rdquo; on page 9 for more information. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus on page&nbsp;8 for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital Market trading symbol</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;CTXR&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The number of shares of our common stock that will be outstanding immediately after this offering assumes the exercise in full of all of the Warrants and Underwriter Warrants and is based on 134,701,219 shares of our common stock outstanding as of March 31, 2021 and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
                                            for 51,569,059 shares of our common stock, with a weighted average exercise price of $1.672
                                            per share (subsequent to March 31, 2021, an aggregate of 10,208,210 shares of our common
                                            stock were issued upon the exercise of warrants for aggregate proceeds of $15,187,567);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">options
                                            to purchase an aggregate of 4,615,171 shares of our common stock issued to our officers,
                                            directors and non-employee consultants under our 2014, 2018, and 2020 Stock Incentive Plans,
                                            with a weighted average exercise price of $2.133 per share (subsequent to March 31, 2021,
                                            an aggregate of 70,000 shares of our common stock were issued upon the exercise of options
                                            for aggregate proceeds of $82,634); and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,240,000
                                            shares of common stock available for future grants under our 2020 Stock Incentive Plan (subsequent
                                            to March 31, 2021, we issued options for the purchase of up to 110,000 shares of our common
                                            stock at an exercise price of $2.50 per share).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On May 24, 2021, our stockholders approved the Citius Pharmaceuticals, Inc. 2021 Omnibus Stock Incentive Plan, which authorizes us to grant up to 8,740,000 shares of common stock, which consists of 7,500,000 shares of common stock reserved for the 2021 Omnibus Stock Incentive Plan and the 1,240,000 shares that remained available under the 2020 Omnibus Stock Incentive Plan on May 24, 2021. Upon approval of the 2021 Omnibus Stock Incentive Plan, the 2020 Omnibus Stock Incentive Plan was terminated. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="G_005"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Investing in our securities involves a high degree of risk. You should
consider carefully the risks and uncertainties described in &ldquo;Risk Factors&rdquo; in our most recently filed Annual Report on Form
10-K filed with the SEC, in each case as these risk factors are amended or supplemented by subsequent Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, or Current Reports on Form 8-K that have been or will be incorporated by reference in this prospectus. The risks
incorporated herein by reference are those which we believe are the material risks that we face. The occurrence of any of such risks may
materially and adversely affect our business, financial condition, results of operations and future prospects. In such an event, the market
price of our common stock could decline, and you could lose part or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may receive up to a total of approximately $6,994,033 in gross proceeds
if all of the Warrants and Underwriter Warrants are exercised for cash. However, as we are unable to predict the timing or amount of potential
exercises of the Warrants or the Underwriter Warrants, we have not allocated any proceeds of such exercises to any particular purpose.
Accordingly, all such proceeds are allocated to working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to conditions set forth in the Warrants and the Underwriter
Warrants, the Warrants and the Underwriter Warrants are exercisable under certain circumstances on a cashless basis, and should a holder
elect to exercise on a cashless basis we will not receive any proceeds from the sale of common stock issued upon such cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will incur all costs associated with this prospectus and the registration
statement of which it is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="G_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All of the securities offered by this prospectus&nbsp;are
being offered and sold directly by us, without an underwriter.&nbsp;The holders of the Warrants and Underwriter Warrants may purchase
the shares of our common stock directly from us by exercising their outstanding Warrants and Underwriter Warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="G_008"></A>DESCRIPTION OF OUR CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description summarizes the material terms of our capital
stock as of the date of this prospectus. Because it is only a summary, it does not contain all the information that may be important to
you. For a complete&nbsp;description of our capital stock, you should refer to our articles of incorporation and our bylaws, and to the
provisions of applicable Nevada law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized capital stock consists of (i) 400,000,000 shares of
common stock, par value $0.001, of which 134,701,219 shares were issued and outstanding as of March 31, 2021, and 144,979,429 shares were
issued and outstanding as of June 25, 2021, and (ii) 10,000,000 shares of preferred stock, par value $0.001, none of which are issued
and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our preferred stock and/or common stock may be issued from time to
time without prior approval by our stockholders. Our preferred stock and/or common stock may be issued for such consideration as may be
fixed from time to time by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are authorized to issue 400,000,000 shares of common stock, $0.001
par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of common stock has one vote per share for all purposes.
The holders of a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at all
meetings of our stockholders. Our common stock does not provide preemptive, subscription or conversion rights and there are no redemption
or sinking fund provisions or rights. Our common stockholders are not entitled to cumulative voting for election of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of common stock are entitled to receive ratably such dividends
as may be declared by the Board of Directors out of funds legally available therefor as well as any distributions to the security holders.
We have never paid cash dividends on our common stock, and do not expect to pay such dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of a liquidation, dissolution or winding up of our company,
holders of common stock are entitled to share ratably in all of our assets remaining after payment of liabilities. Holders of common stock
have no preemptive or other subscription or conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are authorized to issue 10,000,000 shares of preferred stock. Our
Board of Directors is authorized to cause us to issue, from our authorized but unissued shares of preferred stock, one or more series
of preferred stock, to establish from time to time the number of shares to be included in each such series, as well as to fix the designation
and any preferences, conversion and other rights and limitations of such series. These rights and limitations may include voting powers,
limitations as to dividends, and qualifications and terms and conditions of redemption of the shares of each such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2021, under the Company&rsquo;s 2014 Stock Incentive
Plan,&nbsp;2018 Omnibus Stock Incentive Plan,&nbsp;and 2020 Omnibus Stock Incentive Plan,&nbsp;we had outstanding options to purchase
an aggregate of 4,615,171 shares of our common stock at a weighted average exercise price of $2.133 per share. Of these, an aggregate
of 1,968,804 options are exercisable. The remainder has vesting requirements. No more grants may be made under our 2014 Stock Incentive
Plan, 2018 Omnibus Stock Incentive Plan or 2020 Omnibus Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 24, 2021, our stockholders approved the 2021 Omnibus Stock Inventive
Plan which authorizes us to grant up to 8,740,000 shares of common stock, which consists of 7,500,000 shares of common stock reserved
for the 2021 Omnibus Stock Incentive Plan and the 1,240,000 shares that remained available under the 2020 Omnibus Stock Incentive Plan
on May 24, 2021. Upon approval of the 2021 Omnibus Stock Incentive Plan, the 2020 Omnibus Stock Incentive Plan was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsequent to March 31, 2021, 70,000 shares of our common stock were
issued upon the exercise of options for aggregate proceeds of $82,634, and we issued options to purchase up to an aggerate of 110,000
shares of our common stock to employees and advisors with an exercise price of $2.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As of March 31, 2021, we had outstanding warrants to purchase an aggregate
of 51,569,059 shares of our common stock at a weighted average price of $1.672 per share, with a weighted average remaining life of 4.3
years. Subsequent to March 31, 2021, 10,208,210 shares of our common stock were issued upon the exercise of warrants for aggregate proceeds
of $15,187,567.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Trading Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The shares of our common stock are currently listed on the Nasdaq Capital
Market under the symbol &ldquo;CTXR&rdquo; and certain of our warrants issued in August 2017 are currently listed on the Nasdaq Capital
Market under the symbol &ldquo;CTXRW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The transfer agent of our common stock is VStock Transfer. Their address
is 18 Lafayette Place, Woodmere, NY 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Nevada&rsquo;s Anti-Takeover Law and Provisions of Our Articles
of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Acquisition of Controlling Interest Statutes.</I>&nbsp;Nevada&rsquo;s
&ldquo;acquisition of controlling interest&rdquo; statutes contain provisions governing the acquisition of a controlling interest in certain
Nevada corporations. These &ldquo;control share&rdquo; laws provide generally that any person that acquires a &ldquo;controlling interest&rdquo;
in certain Nevada corporations may be denied certain voting rights, unless a majority of the disinterested stockholders of the corporation
elects to restore such voting rights. These statutes provide that a person acquires a &ldquo;controlling interest&rdquo; whenever a person
acquires shares of a subject corporation that, but for the application of these provisions of the Nevada Revised Statutes, would enable
that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority
or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds,
shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the
acquiring person acquired or offered to acquire a controlling interest become &ldquo;control shares&rdquo; to which the voting restrictions
described above apply. Our articles of incorporation and bylaws currently contain no provisions relating to these statutes, and unless
our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest were to provide otherwise,
these laws would apply to us if we were to (i) have 200 or more stockholders of record (at least 100 of which have addresses in the State
of Nevada appearing on our stock ledger) and (ii) do business in the State of Nevada directly or through an affiliated corporation. As
of June 28, 2021, we had 95 record stockholders and did not have 100 stockholders of record with Nevada addresses appearing on our stock
ledger. If these laws were to apply to us, they might discourage companies or persons interested in acquiring a significant interest in
or control of the Company, regardless of whether such acquisition may be in the interest of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Combination with Interested Stockholders Statutes</I>. Nevada&rsquo;s
&ldquo;combinations with interested stockholders&rdquo; statutes prohibit certain business &ldquo;combinations&rdquo; between certain
Nevada corporations and any person deemed to be an &ldquo;interested stockholder&rdquo; for two years after such person first becomes
an &ldquo;interested stockholder&rdquo; unless (i) the corporation&rsquo;s Board of Directors approves the combination (or the transaction
by which such person becomes an &ldquo;interested stockholder&rdquo;) in advance, or (ii) the combination is approved by the Board of
Directors and sixty percent of the corporation&rsquo;s voting power not beneficially owned by the interested stockholder, its affiliates
and associates. Furthermore, in the absence of prior approval, certain restrictions may apply even after such two-year period. For purposes
of these statutes, an &ldquo;interested stockholder&rdquo; is any person who is (x) the beneficial owner, directly or indirectly, of ten
percent or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or associate of the corporation
and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent or more of the voting power
of the then outstanding shares of the corporation. The definition of the term &ldquo;combination&rdquo; is sufficiently broad to cover
most significant transactions between the corporation and an &ldquo;interested stockholder&rdquo;. Subject to certain timing requirements
set forth in the statutes, a corporation may elect not to be governed by these statutes. We have not included any such provision in our
articles of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The effect of these statutes may be to potentially discourage parties
interested in taking control of the Company from doing so if it cannot obtain the approval of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Articles of Incorporation and Bylaws </I>Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change of control or change in our management,
including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders
might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock.
Among other things, these provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            authorization of 10,000,000 shares of &ldquo;blank check&rdquo; preferred stock, the rights,
                                            preferences and privileges of which may be established and shares of which may be issued
                                            by our Board of Directors at its discretion from time to time and without stockholder approval;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">limiting
                                            the removal of directors by the stockholders;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">allowing
                                            for the creation of a staggered Board of Directors;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">eliminating
                                            the ability of stockholders to call a special meeting of stockholders; and</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing
                                            advance notice requirements for nominations for election to the Board of Directors or for
                                            proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_009"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The validity of the securities being offered hereby will be passed
upon by Wyrick Robbins Yates &amp; Ponton LLP, Raleigh, North Carolina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_010"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements of Citius Pharmaceuticals, Inc. appearing
in our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, have been included herein by reference in reliance on
the report of Wolf &amp; Company, P.C., independent registered public accounting firm, given on the authority of such firm as experts
in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_011"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the reporting requirements of the Exchange Act and
file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including
the registration statement, of which this prospectus is a part, over the Internet at the SEC&rsquo;s website at <I>http://www.sec.gov</I>.
We also maintain a website at <I>http://www.citiuspharma.com</I>, at which you may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed
through, our website is not part of this prospectus. You may also request a copy of these filings, at no cost, by writing or telephoning
us at: 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, (908) 967-6677.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="G_012"></A>INCORPORATION OF DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo; information
that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other
documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with
the SEC will automatically update and supersede this information. We filed a registration statement on Form S-3 under the&nbsp;Securities
Act&nbsp;with the SEC with respect to the securities being offered pursuant to this prospectus. This prospectus omits certain information
contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits,
for further information about us and the securities being offered pursuant to this prospectus. Statements in this prospectus regarding
the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete,
and reference is made to the actual documents for complete information. Copies of all or any part of the registration statement, including
the documents incorporated therein by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of
the SEC listed above in &ldquo;Where You Can Find Additional Information.&rdquo; The documents we are incorporating by reference into
this prospectus are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000147793217003565/ctxr_8a12b.htm">Form 8-A</A>, filed
                                            on July 28, 2017;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020043004/f10k2020_citiuspharma.htm">Form 10-K</A> for the fiscal year ended September 30, 2020, filed with the SEC
                                            pursuant to Section 13 of the Exchange Act on December 16, 2020;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021008453/f10q1220_citiuspharma.htm">Form 10-Q</A> for the quarter ended December 31, 2020, filed with the SEC
                                            pursuant to Section 13 of the Exchange Act on February 11, 2021;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021025920/f10q0321_citiuspharma.htm">Form 10-Q</A> for the quarter ended March 31, 2021, filed with the SEC pursuant
                                            to Section 13 of the Exchange Act on May 13, 2021;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our Current Reports on Form 8-K, filed with the SEC pursuant to Section
                                                                                                                                     13 of the Exchange Act on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020030802/ea128020-8k_citiuspharma.htm">October
                                                                                                                                     9</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020033152/ea128836-8k_citiuspharma.htm">October 26</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020039812/ea130603-8k_citiuspharma.htm">November
                                                                                                                                     30</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020041492/ea131047-8k_citius.htm">December 8</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020041804/ea131280-8k_citiuspharma.htm">December
                                                                                                                                     9</A>, 2020, and <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021001319/ea132720-8k_citiuspharma.htm">January
                                                                                                                                     11</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021004622/ea133853-8k_citius.htm">January 27</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021007735/ea135005-8k_citiuspharma.htm">February
                                                                                                                                     9</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021009291/ea135617-8k_citiuspharma.htm">February 16</A> (but
                                                                                                                                     not Item 7.01), <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021010620/ea135915-8k_citiuspharma.htm">February
                                                                                                                                     19</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021028615/ea141564-8k_citiuspharma.htm">May 24</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021031157/ea142288-8k_citiuspharma.htm">June
                                                                                                                                     7</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021031359/ea142344-8k_citius.htm">June 8</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021033563/ea143024-8ka_citiuspharma.htm">June
                                                                                                                                     22</A> (Form 8-K/A), <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021035203/ea143606-8k_citiuspharma.htm">July
                                                                                                                                     1</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021035885/ea143807-8k_citiuspharma.htm">July 7</A> (but not Item 7.01), <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390021035885/ea143807-8k_citiuspharma.htm">2021</A>; and</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                        </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1506251/000121390020043792/ea131488-def14a_citiuspharma.htm">Schedule 14A</A> for the annual meeting of stockholders held on
                                            February 9, 2021, filed with the SEC pursuant to Section 14 of the Exchange Act on December
                                            21, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, all documents subsequently filed by us pursuant to Section
13(a), 13(c), 14 or 15(d) of the&nbsp;Exchange Act&nbsp;before the date this offering is terminated or completed are deemed to be incorporated
by reference into, and to be a part of, this prospectus, provided that that we are not incorporating by reference any information furnished
to, but not filed with, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any statement contained in this prospectus or in a document incorporated
or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated
by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except
as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will furnish without charge to you, on written or oral request,
a copy of any or all of the documents incorporated by reference in the registration statement or this prospectus, including exhibits to
these documents. You should direct any requests for documents to Citius Pharmaceuticals, Inc., Attention: Secretary, 11 Commerce Drive,
1<SUP>st</SUP> Floor, Cranford, New Jersey 07016, (908) 967-6677.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on information contained in, or incorporated by
reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus
or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an
offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone
to whom it is unlawful to make such offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U 4H# 2(  A$! Q$!_\0
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M+P9=7.J^7X8\,^*?%.A2OH>MZ-K&C:O'$_P_^(7]OO% ?"WBYF7QKXLU>/\
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MS;HM4_X1#P[I&O>*8H03#XN\8Z-X=\&O&!<NX_S:O^"T?_*:']N__L\#5O\
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MH4FO8?P[XC\(>)&9O&;>$BO@WQB[>*'\=%6_X0P^#?Z;_P#@GK\;?A7\)?\
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MRCFGS=6N5.4EL]OZVL?8YCB\:O#M2Q<G_;+Y>65Y)N[7+M)-W33O=^1TW_!
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MW49_DH^!WCO5/@%\8_A1\:+&QNM-N/!WB_PO\0;0V=I_9AUWPOH>M$:[HO\
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M+Q7\?O E[:KC[!I7Q8\8?\+S\#:KHF200(M=7!"JP.AMD\ C^\;]@?\ 9?\
M!'QX^._[*?\ P4>_9AUWPU<?LX?%;P-J_P 6/'OA_2-6==0^&OQBU[P7_8GC
M?X9+HS@*X_X6#KVL^9X9C+1>"I?#_BM-V?%?@X+O_P#!>[_@AW%_P4[\,Z9\
M7_@7<^&O!/[7?PS\*ZIX?TF[\6QI8>%OC5X!.[6]$\$>,=8)D/A[Q)X1\0:Q
MK;^!/%1A:-#XA\0>$/&O_%&^)XIK?^&SP1K?_!<'_@C+XR\0^%O 7AG]K/\
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M_7K?_P#IKK^.C_@T1_9^_:!_9N^#/[9>E?M!_ 7XV_ C4?&OQ3^%^L^&]/\
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%DOR1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
